KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Merck (MRK) over the last 17 years, with Q3 2025 value amounting to $532.0 million.

  • Merck's Depreciation & Amortization (CF) fell 379.75% to $532.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 47.98%. This contributed to the annual value of $2.1 billion for FY2024, which is 1509.85% up from last year.
  • Latest data reveals that Merck reported Depreciation & Amortization (CF) of $532.0 million as of Q3 2025, which was down 379.75% from $518.0 million recorded in Q2 2025.
  • Over the past 5 years, Merck's Depreciation & Amortization (CF) peaked at $553.0 million during Q3 2024, and registered a low of $371.0 million during Q2 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $474.0 million (2022), whereas its average is $468.8 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first tumbled by 6459.92% in 2021, then surged by 2776.28% in 2022.
  • Quarter analysis of 5 years shows Merck's Depreciation & Amortization (CF) stood at $452.0 million in 2021, then decreased by 4.87% to $430.0 million in 2022, then rose by 16.74% to $502.0 million in 2023, then grew by 3.98% to $522.0 million in 2024, then increased by 1.92% to $532.0 million in 2025.
  • Its Depreciation & Amortization (CF) was $532.0 million in Q3 2025, compared to $518.0 million in Q2 2025 and $502.0 million in Q1 2025.